89 related articles for article (PubMed ID: 2852508)
1. Recombinant polyoma--vaccinia viruses: T antigen expression vectors and anti-tumor immunization agents.
Clertant P; Kieny MP; Lecocq JP; Guizani I; Chambon P; Cuzin F; Lathe R
Biochimie; 1988 Aug; 70(8):1075-87. PubMed ID: 2852508
[TBL] [Abstract][Full Text] [Related]
2. Vaccination against polyoma virus (PyV) tumors using vaccinia-PyV recombinants: a major tumor-specific transplantation antigen (TSTA) epitope resides within the C-terminal segment of middle-T protein.
Kieny MP; Gautier C; Tomasetto C; Kuhn I; Hareuveni M; Clertant P; Lathe R
Int J Cancer; 1990 Jan; 45(1):185-9. PubMed ID: 1688831
[TBL] [Abstract][Full Text] [Related]
3. Tumour prevention and rejection with recombinant vaccinia.
Lathe R; Kieny MP; Gerlinger P; Clertant P; Guizani I; Cuzin F; Chambon P
Nature; 1987 Apr 30-May 6; 326(6116):878-80. PubMed ID: 3033512
[TBL] [Abstract][Full Text] [Related]
4. Immunization against the polyoma tumor-specific transplantation antigen (TSTA) with polyoma T-antigens.
Ramqvist T; Pallas DO; DeAnda J; Ahrlund-Richter L; Reinholdsson G; Roberts TM; Schaffhausen BS; Dalianis T
Int J Cancer; 1988 Jul; 42(1):123-8. PubMed ID: 2839427
[TBL] [Abstract][Full Text] [Related]
5. Characterization of polyoma virus early proteins expressed from vaccinia virus recombinants.
Guizani I; Kieny MP; Lathe R; Clertant P
Gene; 1988 Dec; 73(1):163-73. PubMed ID: 2977356
[TBL] [Abstract][Full Text] [Related]
6. Vaccinia recombinants expressing early bovine papilloma virus (BPV1) proteins: retardation of BPV1 tumour development.
Meneguzzi G; Kieny MP; Lecocq JP; Chambon P; Cuzin F; Lathe R
Vaccine; 1990 Jun; 8(3):199-204. PubMed ID: 2163573
[TBL] [Abstract][Full Text] [Related]
7. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
8. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
[TBL] [Abstract][Full Text] [Related]
9. An adenovirus vector system used to express polyoma virus tumor antigens.
Mansour SL; Grodzicker T; Tjian R
Proc Natl Acad Sci U S A; 1985 Mar; 82(5):1359-63. PubMed ID: 2983341
[TBL] [Abstract][Full Text] [Related]
10. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7.
Meneguzzi G; Cerni C; Kieny MP; Lathe R
Virology; 1991 Mar; 181(1):62-9. PubMed ID: 1847269
[TBL] [Abstract][Full Text] [Related]
11. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.
Chen CH; Wang TL; Ji H; Hung CF; Pardoll DM; Cheng WF; Ling M; Wu TC
Gene Ther; 2001 Jan; 8(2):128-38. PubMed ID: 11313782
[TBL] [Abstract][Full Text] [Related]
12. Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein.
Hany M; Oehen S; Schulz M; Hengartner H; Mackett M; Bishop DH; Overton H; Zinkernagel RM
Eur J Immunol; 1989 Mar; 19(3):417-24. PubMed ID: 2468501
[TBL] [Abstract][Full Text] [Related]
13. Protective efficacy of a recombinant vaccinia virus in vaccinia-immune mice.
Andrew ME
Immunol Cell Biol; 1989 Oct; 67 ( Pt 5)():339-41. PubMed ID: 2613281
[TBL] [Abstract][Full Text] [Related]
14. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.
Paoletti E; Lipinskas BR; Samsonoff C; Mercer S; Panicali D
Proc Natl Acad Sci U S A; 1984 Jan; 81(1):193-7. PubMed ID: 6320164
[TBL] [Abstract][Full Text] [Related]
15. Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity.
Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
Eur J Immunol; 1988 Nov; 18(11):1773-8. PubMed ID: 2974424
[TBL] [Abstract][Full Text] [Related]
16. Vaccination against tumor cells expressing breast cancer epithelial tumor antigen.
Hareuveni M; Gautier C; Kieny MP; Wreschner D; Chambon P; Lathe R
Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9498-502. PubMed ID: 2251291
[TBL] [Abstract][Full Text] [Related]
17. B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.
Viner KM; Girgis N; Kwak H; Isaacs SN
Virology; 2007 May; 361(2):356-63. PubMed ID: 17188733
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate.
Kantor J; Irvine K; Abrams S; Snoy P; Olsen R; Greiner J; Kaufman H; Eggensperger D; Schlom J
Cancer Res; 1992 Dec; 52(24):6917-25. PubMed ID: 1458480
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J
Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410
[TBL] [Abstract][Full Text] [Related]
20. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
